ACL Capabilities

Home > Proteins and Proteomics > Antibody Characterization Laboratory (ACL) > ACL Capabilities

The Antibody Characterization Laboratory activities cover the breadth of monoclonal antibody production and characterization. Antibodies are directed to relevant, cancer-related antigens. More information about the laboratory’s processes can be found at: http://antibodies.cancer.gov/.

NCI’s Office of Cancer Clinical Proteomics Research funds the activity of the ACL, as a resource to the entire cancer research community.

Antibody Characterization Capabilities:

Antibodies characterized using robust developed and SOP-driven procedures

Antibody-specific activity calculated from indirect ELISA titration for binding and antibody concentration assays
Western blot using homologous antigen, and antibody
PAGE for purity
Isotype analysis

Data reviewed, approved, and distributed:

Open resource characterization data:
http://antibodies.cancer.gov/

ACL Expertise

Design, development, and deployment of FDA approved immunoassays and assay systems
cGMP design of reagents and documentation
Clinical laboratory operation and management

Characterization through internal collaborations

SPR analysis for binding affinity measurements
Immuno MALDI
Tissue array (reverse phase) with NCI 60
IHC where appropriate

Characterization through external collaborations:

Protein arrays by Arizona State University
Tissue IHC by the Human Proteome Atlase

Antibodies and cell lines available:

Distributed by Developmental Studies Hybridoma Bank, University of Iowa (http://dshb.biology.uiowa.edu) for Research Use Only
Commercially available by non-exclusive license from NCI’s Office of Cancer Clinical Proteomics Research (Email cancer.proteomics@mail.nih.gov for more information.)

Advanced Technology Program (ATP)